Homeobox gene HOPX is epigenetically silenced in human uterine endometrial cancer and suppresses estrogen-stimulated proliferation of cancer cells by inhibiting serum response factor

International Journal of Cancer

Volumn 124, Issue 11, 2009, Pages 2577-2588

  Yamaguchi, Shinichiro ^a   Asanoma, Kazuo ^b,c   Takao, Tomoka ^a   Kato, Kiyoko ^b   Wake, Norio ^a  

^a KYUSHU UNIVERSITY   (Japan)

^b KYUSHU UNIVERSITY   (Japan)

^c UNIVERSITY OF KANSAS SCHOOL OF MEDICINE   (United States)

Author keywords

17 estradiol; DNA methylation; HOPX; Human uterine endometrial cancer; Serum response factor; Tumor suppressor gene

Indexed keywords

ESTRADIOL; HOMEODOMAIN PROTEIN; MESSENGER RNA; SERUM RESPONSE FACTOR; HOP PROTEIN, HUMAN; PROTEIN C FOS; TUMOR SUPPRESSOR PROTEIN;

ARTICLE; CANCER CELL; CARCINOGENICITY; CELL PROLIFERATION; CELL STIMULATION; CELL STRAIN MCF 7; ENDOMETRIUM CANCER; EPIGENETICS; FEMALE; GENE ACTIVATION; GENE EXPRESSION; GENE SILENCING; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VIVO STUDY; INHIBITION KINETICS; LASER CAPTURE MICRODISSECTION; METHYLATION; MUTATION; ONCOGENE C FOS; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN MOTIF; SERUM RESPONSIVE ELEMENT; TUMOR SUPPRESSOR GENE; DNA METHYLATION; DRUG ANTAGONISM; DRUG EFFECT; ENDOMETRIUM TUMOR; GENETIC EPIGENESIS; GENETICS; PATHOLOGY; PHYSIOLOGY; TUMOR CELL LINE;

CELL LINE, TUMOR; CELL PROLIFERATION; DNA METHYLATION; ENDOMETRIAL NEOPLASMS; EPIGENESIS, GENETIC; ESTRADIOL; FEMALE; GENE SILENCING; HOMEODOMAIN PROTEINS; HUMANS; PROMOTER REGIONS, GENETIC; PROTO-ONCOGENE PROTEINS C-FOS; RNA, MESSENGER; SERUM RESPONSE FACTOR; TUMOR SUPPRESSOR PROTEINS;

EID: 64249126794     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.24217     Document Type: Article

References (43)

1. Jones PA, Baylin SB. The fundamental role of epigenetic events in cancer. Nat Rev Genet 2002;3:415-428 (Pubitemid 34587077)
2. Ushijima T. Detection and interpretation of altered methylation patterns in cancer cells. Nat Rev Cancer 2005;5:223-231 (Pubitemid 40314953)
3. Bamberger AM, Bamberger CM, Schulte HM. Molecular mechanisms of proliferation in endometrial tumour cells. Hum Reprod Update 1998;4:526-531 (Pubitemid 29041465)
4. Nemos C, Delage-Mourroux R, Jouvenot M, Adami P. Onset of direct 17-beta estradiol effects on proliferation and c-fos expression during oncogenesis of endometrial glandular epithelial cells. Exp Cell Res 2004;296:109-122 (Pubitemid 38624633)
5. Shiozawa T, Miyamoto T, Kashima H, Nakayama K, Nikaido T, Konishi I. Estrogen-induced proliferation of normal endometrial glandular cells is initiated by transcriptional activation of cyclin D1 via binding of c-Jun to an AP-1 sequence. Oncogene 2004;23:8603-8610 (Pubitemid 39576467)
6. Shen Q, Uray IP, Li Y, Krisko TI, Strecker TE, Kim HT, Brown PH. The AP-1 transcription factor regulates breast cancer cell growth via cyclins and E2F factors. Oncogene 2008;27:366-377
7. Maggiolini M, Vivacqua A, Fasanella G, Recchia AG, Sisci D, Pezzi V, Montanaro D, Musti AM, Picard D, Ando S. The G protein-coupled receptor GPR30 mediates c-fos up-regulation by 17beta-estradiol and phytoestrogens in breast cancer cells. J Biol Chem 2004;279:27008-27016 (Pubitemid 38812536)
8. Gründker C, Günthert AR, Hellriegel M, Emons G. Gonadotropin-releasing hormone (GnRH) agonist triptorelin inhibits estradiol-induced serum response element (SRE) activation and c-fos expression in human endometrial, ovarian and breast cancer cells. Eur J Endocrinol 2004;151:619-628 (Pubitemid 39562518)
9. Duan R, Xie W, Burghardt RC, Safe S. Estrogen receptor-mediated activation of the serum response element in MCF-7 cells through MAPK-dependent phosphorylation of Elk-1. J Biol Chem 2001;276:11590-11598 (Pubitemid 37385310)
10. Duan R, Xie W, Li X, McDougal A, Safe S. Estrogen regulation of cfos gene expression through phosphatidylinositol-3-kinase-dependent activation of serum response factor in MCF-7 breast cancer cells. Biochem Biophys Res Commun 2002;294:384-394 (Pubitemid 34694107)
11. Hill CS, Marais R, John S, Wynne J, Dalton S, Treisman R. Functional analysis of a growth factor-responsive transcription factor complex. Cell 1993;73:395-406. (Pubitemid 23123316)
12. Poser S, Impey S, Trinh K, Xia Z, Storm DR. SRF-dependent gene expression is required for PI3-kinase-regulated cell proliferation. EMBO J 2000;19:4955-4966
13. Chen F, Kook H, Milewski R, Gitler AD, Lu MM, Li J, Nazarian R, Schnepp R, Jen K, Biben C, Runke G, Mackay JP, et al. Hop is an unusual homeobox gene that modulates cardiac development. Cell 2002;110:713-723 (Pubitemid 35283961)
14. Shin CH, Liu ZP, Passier R, Zhang CL, Wang DZ, Harris TM, Yamagishi H, Richardson JA, Childs G, Olson EN. Modulation of cardiac growth and development by HOP, an unusual homeodomain protein. Cell 2002;110:725-735 (Pubitemid 35283962)
15. Kook H, Lepore JJ, Gitler AD, Lu MM, Wing-Man Yung W, Mackay J, Zhou R, Ferrari V, Gruber P, Epstein JA. Cardiac hypertrophy and histone deacetylase-dependent transcriptional repression mediated by the atypical homeodomain protein Hop. J Clin Invest 2003;112:863-871 (Pubitemid 38063744)
16. Asanoma K, Matsuda T, Kondo H, Kato K, Kishino T, Niikawa N, Wake N, Kato H. NECC1, a candidate choriocarcinoma suppressor gene that encodes a homeodomain consensus motif. Genomics 2003;81:15-25. (Pubitemid 36263355)
17. Chen Y, Petersen S, Pacyna-Gengelbach M, Pietas A, Petersen I. Identification of a novel homeobox-containing gene, LAGY, which is downregulated in lung cancer. Oncology 2003;64:450-458 (Pubitemid 36682961)
18. Lemaire F, Millon R, Muller D, Rabouel Y, Bracco L, Abecassis J, Wasylyk B. Loss of HOP tumour suppressor expression in head and neck squamous cell carcinoma. Br J Cancer 2004;91:258-261 (Pubitemid 39037069)
19. Toruner GA, Ulger C, Alkan M, Galante AT, Rinaggio J, Wilk R, Tian B, Soteropoulos P, Hameed MR, Schwalb MN, Dermody JJ. Association between gene expression profile and tumor invasion in oral squamous cell carcinoma. Cancer Genet Cytogenet 2004;154:27-35. (Pubitemid 39286169)
20. Yamashita K, Kim MS, Park HL, Tokumaru Y, Osada M, Inoue H, Mori M, Sidransky D. HOP/OB1/NECC1 promoter DNA is frequently hypermethylated and involved in tumorigenic ability in esophageal squamous cell carcinoma. Mol Cancer Res 2008;6:31-41.
21. Kyo S, Nakamura M, Kiyono T, Maida Y, Kanaya T, Tanaka M, Yatabe N, Inoue M. Successful immortalization of endometrial glandular cells with normal structural and functional characteristics. Am J Pathol 2003;163:2259-2269 (Pubitemid 37466470)
22. Asanoma K, Kato H, Yamaguchi S, Shin CH, Liu ZP, Kato K, Inoue T, Miyanari Y, Yoshikawa K, Sonoda K, Fukushima K, Wake N. HOP/NECC1, a novel regulator of mouse trophoblast differentiation. J Biol Chem 2007;282:24065-24074 (Pubitemid 47328046)
23. Wilkinson DG, Nieto MA. Detection of messenger RNA by in situ hybridization to tissue sections and whole mounts. Methods Enzymol 1993;225:361-373 (Pubitemid 23301534)
24. Yin Z, Gonzales L, Kolla V, Rath N, Zhang Y, Lu MM, Kimura S, Ballard PL, Beers MF, Epstein JA, Morrisey EE. Hop functions downstream of Nkx2.1 and GATA6 to mediate HDAC-dependent negative regulation of pulmonary gene expression. Am J Physiol Lung Cell Mol Physiol 2006;291:L191-9. (Pubitemid 44148103)
25. Vivacqua A, Bonofiglio D, Recchia AG, Musti AM, Picard D, Andòs, Maggiolini M. The G protein-coupled receptor GPR30 mediates the proliferative effects induced by 17beta-estradiol and hydroxytamoxifen in endometrial cancer cells. Mol Endocrinol 2006;20:631-646
26. Horner-Glister E, Maleki-Dizaji M, Guerin CJ, Johnson SM, Styles J, White IN. Influence of oestradiol and tamoxifen on oestrogen receptors- alpha and -beta protein degradation and non-genomic signaling pathways in uterine and breast carcinoma cells. J Mol Endocrinol 2005;35:421-432 (Pubitemid 43025569)
27. Kanaya T, Kyo S, Maida Y, Yatabe N, Tanaka M, Nakamura M, Inoue M. Frequent hypermethylation of MLH1 promoter in normal endometrium of patients with endometrial cancers. Oncogene 2003;22:2352-2360 (Pubitemid 36566790)
28. Arafa M, Kridelka F, Mathias V, Vanbellinghen JF, Renard I, Foidart JM, Boniver J, Delvenne P. High frequency of RASSF1A and RARb2 gene promoter methylation in morphologically normal endometrium adjacent to endometrioid adenocarcinoma. Histopathology 2008;53:525-532
29. Mutter GL, Ince TA, Baak JP, Kust GA, Zhou XP, Eng C. Molecular identification of latent precancers in histologically normal endometrium. Cancer Res 2001;61:4311-4314 (Pubitemid 32685749)
30. Talbi S, Hamilton AE, Vo KC, Tulac S, Overgaard MT, Dosiou C, Le Shay N, Nezhat CN, Kempson R, Lessey BA, Nayak NR, Giudice LC. Molecular phenotyping of human endometrium distinguishes menstrual cycle phases and underlying biological processes in normoovulatory women. Endocrinology 2006;147:1097-1121 (Pubitemid 43244341)
31. Chen Y, Pacyna-Gengelbach M, Deutschmann N, Niesporek S, Petersen I. Homeobox gene HOP has a potential tumor suppressive activity in human lung cancer. Int J Cancer 2007;121:1021-1027
32. Urich M, Senften M, Shaw PE, Ballmer-Hofer K. A role for the small GTPase Rac in polyomavirus middle-T antigen-mediated activation of the serum response element and in cell transformation. Oncogene 1997;14:1235-1241 (Pubitemid 27141927)
33. Ding W, Witte MM, Scott RE. Transformation blocks differentiation-induced inhibition of serum response factor interactions with serum response elements. Cancer Res 1999;59:3795-3802 (Pubitemid 29381889)
34. Iwahara T, Akagi T, Shishido T, Hanafusa H. CrkII induces serum response factor activation and cellular transformation through its function in Rho activation. Oncogene 2003;22:5946-5957 (Pubitemid 37175873)
35. Keller PJ, Gable CM, Wing MR, Cox AD. Rac3-mediated transformation requires multiple effector pathways. Cancer Res 2005;65:9883-9890 (Pubitemid 41541468)
36. Lin H, McGrath J, Wang P, Lee T. Cellular toxicity induced by SRF-mediated transcriptional squelching. Toxicol Sci 2007;96:83-91. (Pubitemid 46323211)
37. Lowe WL, Jr, Fu R, Banko M. Growth factor-induced transcription via the serum response element is inhibited by cyclic adenosine 3′,5′- monophosphate in MCF-7 breast cancer cells. Endocrinology 1997;138:2219-2226 (Pubitemid 27215218)
38. Kim B, Leventhal PS, Saltiel AR, Feldman EL. Insulin-like growth factor-I-mediated neurite outgrowth in vitro requires mitogen-activated protein kinase activation. J Biol Chem 1997;272:21268-21273 (Pubitemid 27373992)
39. Wu W, Pew T, Zou M, Pang D, Conzen SD. Glucocorticoid receptorinduced MAPK phosphatase-1 (MPK-1) expression inhibits paclitaxel- associated MAPK activation and contributes to breast cancer cell survival. J Biol Chem 2005;280:4117-4124 (Pubitemid 40288576)
40. Moelling K, Schad K, Bosse M, Zimmermann S, Schweneker M. Regulation of Raf-Akt Cross-talk. J Biol Chem 2002;277:31099-31106 (Pubitemid 34970815)
41. Marino M, Acconcia F, Trentalance A. Biphasic estradiol-induced AKT phosphorylation is modulated by PTEN via MAP kinase in HepG2 cells. Mol Biol Cell 2003;14:2583-2591 (Pubitemid 36724344)
42. Gervais M, Dugourd C, Muller L, Ardidie C, Canton B, Loviconi L, Corvol P, Chneiweiss H, Monnot C. Akt down-regulates ERK1/2 nuclear localization and angiotensin II-induced cell proliferation through PEA-15. Mol Biol Cell 2006;17:3940-3951 (Pubitemid 44330878)
43. Menges CW, McCance DJ. Constitutive activation of the Raf-MAPK pathway causes negative feedback inhibition of Ras-PI3K-AKT and cellular arrest through the EphA(2) receptor. Oncogene 2007;27:2934-2940